EUVIMEDOpdag EUVIMED
Crossref

For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?

Heather Walker

Cochrane Clinical Answers · 2026-07-29

DOI: 10.1002/cca.4802 ↗

At a glance

Journal article in Cochrane Clinical Answers, published online on 2026-07-29. Written by Heather Walker. 10 references.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Intet abstract tilgængeligt.

Cite

APA

Walker, H. (2026). For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4802

Vancouver

Walker H. For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4802

BibTeX
@article{Walker2026,
  author = {Walker, Heather},
  title = {For adults with chronic kidney disease (CKD) and type 2 diabetes, how do dipeptidyl peptidase 4 (DPP-4) inhibitors compare with placebo or standard medical care?},
  journal = {Cochrane Clinical Answers},
  year = {2026},
  doi = {10.1002/cca.4802}
}
Start for free →